ELAB's wholly-owned sub Northstrive Bio UCLA Obesity Symposium - Slideshow Presentation

NorthStrive Biosciences Overview - NorthStrive Biosciences, a division of PMGC Holdings, is focused on developing therapeutics for obesity and aesthetics[6] - The company licensed EL-22, a first-in-class asset designed to preserve muscle during GLP-1 obesity treatments[6] - NorthStrive is actively seeking additional pipeline assets and recruiting experienced team members[6] Obesity Market and Unmet Needs - Nearly half of Americans are projected to suffer from obesity by 2030[7] - Past GLP-1 studies indicate approximately 40% of weight loss is due to loss of lean muscle[9] - Physicians are concerned about patients losing muscle during GLP-1 treatment and regaining fat afterward[9] EL-22 and EL-32 Development - EL-22 is an engineered probiotic expressing modified human myostatin[17, 20, 29] - Preclinical data shows EL-22 inhibits weight loss caused by muscle loss in DMD mice models, improving exercise capacity and muscle strength[31] - In preclinical studies, body weight in EL-22 group increased 10.67g vs 8.29g in control group (p=0.01)[33] - EL-22 Phase 1 clinical trial (n=37) completed in South Korea showed good safety and tolerability profiles up to 2,000 mg/day[35, 43] - EL-32 is an engineered probiotic expressing both Myostatin & Activin-A antigens[19, 44, 46] - Preclinical data for EL-32 in healthy mice showed statistically significant Activin A (p=0.0034) and myostatin (p=0.0047) antibody production[47, 48] Competitive Advantages - NorthStrive Biosciences believes its assets would be the only oral Myostatin formulations to date and be early movers in the emerging GLP-1 combination space[55] - The Myostatin pathway has been validated by the likes of Eli Lilly's $1.9 billion acquisition of Versanis[54]